Vaxcyte (NASDAQ:PCVX) Price Target Raised to $140.00 at Bank of America

Vaxcyte (NASDAQ:PCVX) had its price objective boosted by Bank of America from $101.00 to $140.00 in a report published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on PCVX. Cantor Fitzgerald restated an overweight rating on shares of Vaxcyte in a research note on Thursday, June 20th. Jefferies Financial Group upped their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a buy rating in a research note on Tuesday, September 3rd. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a buy rating in a research note on Tuesday, September 3rd. Needham & Company LLC boosted their target price on Vaxcyte from $95.00 to $140.00 and gave the stock a buy rating in a report on Tuesday, September 3rd. Finally, Leerink Partners increased their price target on Vaxcyte from $106.00 to $153.00 and gave the company an outperform rating in a research note on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $131.83.

Vaxcyte Stock Down 0.5 %

Vaxcyte stock opened at $111.58 on Wednesday. Vaxcyte has a 52-week low of $44.20 and a 52-week high of $119.27. The firm has a market capitalization of $12.14 billion, a price-to-earnings ratio of -26.07 and a beta of 0.97. The firm has a 50-day moving average price of $81.80 and a two-hundred day moving average price of $73.53.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same period last year, the business posted ($0.70) earnings per share. Research analysts expect that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Activity

In other news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Elvia Cowan sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the transaction, the senior vice president now owns 30,826 shares in the company, valued at approximately $2,354,181.62. The disclosure for this sale can be found here. Insiders sold 85,283 shares of company stock worth $7,271,218 over the last quarter. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

A number of institutional investors have recently bought and sold shares of PCVX. Parallel Advisors LLC raised its stake in shares of Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares in the last quarter. Fifth Third Bancorp acquired a new position in Vaxcyte in the second quarter worth approximately $35,000. Fidelis Capital Partners LLC bought a new position in Vaxcyte during the first quarter valued at approximately $37,000. J.Safra Asset Management Corp lifted its stake in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Vaxcyte in the second quarter worth approximately $70,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.